Discovery of small molecule CXCR4 antagonists

Journal of Medicinal Chemistry

Volumn 50, Issue 23, 2007, Pages 5655-5664

  Zhan, Weiqiang ^a   Liang, Zhongxing ^b   Zhu, Aizhi ^b   Kurtkaya, Serdar ^a   Shim, Hyunsuk ^a,b   Snyder, James P ^a   Liotta, Dennis C ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLIC AMP; MATRIGEL; N,N' DI 2 PYRIDINYL 1,4 BENZENEDIMETHANAMINE; STROMAL CELL DERIVED FACTOR 1; TN 14003; UNCLASSIFIED DRUG; WZ 811;

ANALYTIC METHOD; ARTICLE; ASSAY; BINDING AFFINITY; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIPOPHILICITY; METASTASIS; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR CELL;

AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; BENZYLAMINES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CHEMOKINE CXCL12; COLLAGEN; CYCLIC AMP; DRUG COMBINATIONS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; LAMININ; MODELS, MOLECULAR; NEOPLASM INVASIVENESS; PROTEOGLYCANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, CXCR4; STEREOISOMERISM;

EID: 36148957078     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070679i     Document Type: Article

References (58)

1. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-45.
2. Rosenkilde, M. M.; Gerlach, L. O.; Jakobsen, J. S.; Skerlj, R. T.; Bridger, G. J.; Schwartz, T. W. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J. Biol. Chem. 2004, 279, 3033-41.
3. Gerlach, L. O.; Skerlj, R. T.; Bridger, G. J.; Schwartz, T. W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 2001, 276, 14153-60.
4. Tashiro, K.; Tada, H.; Heilker, R.; Shirozu, M.; Nakano, T.; Honjo, T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993, 261, 600-3.
5. Horuk, R. Chemokine receptors. Cytokine Growth Factor Rev. 2001, 12, 313-35.
6. Burns, J. M.; Summers, B. C.; Wang, Y.; Melikian, A.; Berahovich, R.; Miao, Z.; Penfold, M. E.; Sunshine, M. J.; Littman, D. R.; Kuo, C. J.; Wei, K.; McMaster, B. E.; Wright, K.; Howard, M. C.; Schall, T. J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203, 2201-13.
7. De Clercq, E. The bicyclam AMD3100 story. Nat. Rev. Drug Discovery 2003, 2, 581-7.
8. Fujii, N.; Nakashima, H.; Tamamura, H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin. Invest. Drugs 2003, 12, 185-95.
9. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272, 872-7.
10. Oberlin, E.; Amara, A.; Bachelerie, F.; Bessia, C.; Virelizier, J. L.; Arenzana-Seisdedos, F.; Schwartz, O.; Heard, J. M.; Clark-Lewis, I.; Legier, D. F.; Loetscher, M.; Baggiolini, M.; Moser, B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382, 833-5.
11. Tachibana, K.; Hirota, S.; Iizasa, H.; Yoshida, H.; Kawabata, K.; Kataoka, Y.; Kitamura, Y.; Matsushima, K.; Yoshida, N.; Nishikawa, S.; Kishimoto, T.; Nagasawa, T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393, 591-4.
12. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-6.
13. Liang, Z.; Wu, T.; Lou, H.; Yu, X.; Taichman, R. S.; Lau, S. K.; Nie, S.; Umbreit, J.; Shim, H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 2004, 64, 4302-8.
14. Kucia, M.; Jankowski, K.; Reca, R.; Wysoczynski, M.; Bandura, L.; Allendorf, D. J.; Zhang, J.; Ratajczak, J.; Ratajczak, M. Z. CXCR4-SDF-1 signalling, locomotion, Chemotaxis and adhesion. J. Mol. Histol. 2004, 35, 233-45.
15. Trent, J. O.; Wang, Z. X.; Murray, J. L.; Shao, W.; Tamamura, H.; Fujii, N.; Peiper, S. C. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J. Biol. Chem. 2003, 278, 47136-44.
16. Ueda, S.; Oishi, S.; Wang, Z. X.; Araki, T.; Tamamura, H.; Cluzeau, J.; Ohno, H.; Kusano, S.; Nakashima, H.; Trent, J. O.; Peiper, S. C.; Fujii, N. Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J. Med. Chem. 2007, 50, 192-8.
17. Tamamura, H.; Tsutsumi, H.; Masuno, H.; Mizokami, S.; Hiramatsu, K.; Wang, Z.; Trent, J. O.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Fujii, N. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs. Org. Biomol. Chem. 2006, 4, 2354-7.
18. Tamamura, H.; Ojida, A.; Ogawa, T.; Tsutsumi, H.; Masuno, H.; Nakashima, H.; Yamamoto, N.; Hamachi, I.; Fujii, N. Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure. J. Med. Chem. 2006, 49, 3412-5.
19. Tamamura, H.; Hiramatsu, K.; Ueda, S.; Wang, Z.; Kusano, S.; Terakubo, S.; Trent, J. O.; Peiper, S. C.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl) alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J. Med. Chem. 2005, 48, 380-91.
20. Hatse, S.; Princen, K.; Gerlach, L. O.; Bridger, G.; Henson, G.; De Clercq, E.; Schwartz, T. W.; Schols, D. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharmacol. 2001, 60, 164-73.
21. Schwarz, M. K.; Wells, T. N. New therapeutics that modulate chemokine networks. Nat. Rev. Drug Discovery 2002, 1, 347-58.
22. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J. Enzyme Inhib. Med. Chem. 2002, 17, 69-76.
23. Hendrix, C. W.; Flexner, C.; MacFarland, R. T.; Giandomenico, C.; Fuchs, E. J.; Redpath, E.; Bridger, G.; Henson, G. W. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. 2000, 44, 1667-73.
24. Princen, K.; Schols, D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev. 2005, 16, 659-77.
25. De Clercq, E. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. Int. J. Biochem. Cell Biol. 2004, 36, 1800-22.
26. Several of the analogues described in this paper have been synthesized previously; however, none of them have been reported as potential CXCR4 antagonists.
27. Liang, X.; Parkinson, J. A.; Weishaupl, M.; Gould, R. O.; Paisey, S. J.; Park, H. S.; Hunter, T. M.; Blindauer, C. A.; Parsons, S.; Sadler, P. J. Structure and dynamics of metallomacrocycles: recognition of zinc xylyl-bicyclam by an HIV coreceptor. J. Am. Chem. Soc. 2002, 124, 9105-12.
28. Seely, D. M.; Wu, P.; Mills, E. J. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovasc. Disord. 2005, 5, 32.
29. Selig, R. A.; White, L.; Gramacho, C.; Sterling-Levis, K.; Fraser, I. W.; Naidoo, D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res. 1998, 58, 473-8.
30. Grier, M. T.; Meyers, D. G. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann. Pharmacother. 1993, 27, 1504-9.
31. Gerlach, L. O.; Jakobsen, J. S.; Jensen, K. P.; Rosenkilde, M. R.; Skerlj, R. T.; Ryde, U.; Bridger, G. J.; Schwartz, T. W. Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. Biochemistry 2003, 42, 710-7.
32. The basement membrane Matrigel is an extract of the Englebreth-Holm-Swarm mouse sarcoma. Its major component is laminin, followed by collagen IV, heparan sulfate proteoglycans, entactin, and nidogen. For more information, see the following. Kleinman, H. K.; McGarvey, M. L.; Liotta, L. A.; Robey, P. G.; Tryggvason, K.; Martin, G. R. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982, 21, 6188-93.
33. McGuire, P. G.; Seeds, N. W. The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells. J. Cell. Biochem. 1989, 40, 215-7.
34. Mel'nikov, A. A.; Palyulin, V. A.; Zefirov, N. S. Generation of molecular graphs for QSAR studies. Dokl. Chem. 2005, 402, 81-5.
35. Palyulin, V. A.; Radchenko, E. V.; Zefirov, N. S. Molecular field topology analysis method in QSAR studies of organic compounds. J. Chem. Inf. Comput. Sci. 2000, 40, 659-67.
36. Tamamura, H.; Hori, A.; Kanzaki, N.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003, 550, 79-83.
37. Mori, T.; Doi, R.; Koizumi, M.; Toyoda, E.; Ito, D.; Kami, K.; Masui, T.; Fujimoto, K.; Tamamura, H.; Hiramatsu, K.; Fujii, N.; Imamura, M. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol. Cancer Ther. 2004, 3, 29-37.
38. Oonuma, T.; Morimatsu, M.; Nakagawa, T.; Uyama, R.; Sasaki, N.; Nakaichi, M.; Tamamura, H.; Fujii, N.; Hashimoto, S.; Yamamura, H.; Syuto, B. Role of CXCR4 and SDF-1 in mammary tumor metastasis in the cat. J. Vet. Med. Sci. 2003, 65, 1069-73.
39. Braun, C. E.; Erit, J. D.; Crooks, G. C. Guanidine structure and hypoglycemia - Some carbocyclic diguanidines. J. Org. Chem. 1938, 3, 146-52.
40. Murdock, K. C.; Child, R. G.; Lin, Y.; Warren, J. D.; Fabio, P. F.; Lee, V. J.; Izzo, P. T.; Lang, S. A., Jr.; Angier, R. B.; Citarella, R. V.; Wallace, R. E.; Durr, F. E. Antitumor agents. 2. Bisguanylhydrazonesof anthracene-9,10-dicarboxaldehydes. J. Med. Chem. 1982, 25, 505-18.
41. Linton, B. R.; Goodman, M. S.; Fan, E.; van Arman, S. A.; Hamilton, A. D. Thermodynamic aspects of dicarboxylate recognition by simple artificial receptors. J. Org. Chem. 2001, 66, 7313-9.
42. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive animation of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive animation procedures. J. Org. Chem. 1996, 61, 3849-62.
43. Micovic, V. M.; Mihailovic, M. L. The reduction of acid amides with lithium aluminum hydride. J. Org. Chem. 1953, 18, 1190-1200.
44. Zou, R. Y.; Xu, F. B.; Li, Q. S.; Song, H. B.; Lv, H.; Zhang, Z. Z. 1,4-bis(pyridine-2-aminomethyl)benzene. Acta Crystallogr., Sect. E: Struct. Rep. Online 2003, 59, O1312-O1313.
45. Reyes, M. J.; Delgado, F.; Izquierdo, M. L.; Alvarez-Builla, J. Pyridinium N-(2′-azinyl)aminides: regioselective synthesis of N-(2-pyridyl) substituted polyamines. Tetrahedron 2002, 58, 8573-9.
46. Hatse, S.; Princen, K.; Bridger, G.; De Clercq, E.; Schols, D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002, 527, 255-62.
47. Cooper, D. M.; Mons, N.; Karpen, J. W. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature 1995, 374, 421-4.
48. Taussig, R.; Gilman, A. G. Mammalian membrane-bound adenylyl cyclases. J. Biol. Chem. 1995, 270, 1-4.
49. Bohm, H. J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Muller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry. ChemBioChem 2004, 5, 637-43.
50. Maienfisch, P.; Hall, R. G. The importance of fluorine in the life science industry. Chimia 2004, 58, 93-9.
51. Dolbier, W. R. Fluorine - A powerful tool for enhancement of bioactive compounds. Recent advances in the development of CF3 and SF3 fluorinated building blocks. Chim. Oggi 2003, 21, 66-9.
52. David, P.; Mayan, H.; Cohen, H.; Tal, D. M.; Karlish, S. J. D. Guanidinium derivatives act as high-affinity antagonists of Na+ ions in occlusion sites of Na+,K+-ATPase. J. Biol. Chem. 1992, 267, 1141-9.
53. Khownium, K.; Wood, S. J.; Miller, K. A.; Balakrishna, R.; Nguyen, T. B.; Kimbrell, M. R.; Georg, G. I.; David, S. A. Novel endotoxin-sequestering compounds with terephthalaldehyde-bis-guanylhydrazone scaffolds. Bioorg. Med. Chem. Lett. 2006, 16, 1305-8.
54. Lowe, J. L.; Peak, D. A.; Watkins, T. I. Antituberculous compounds. 8. Phenolic 2-diethylaminoethyl ethers and analogues. J. Chem. Soc. 1951, 3286-92.
55. Kawaji, T.; Hayashi, K.; Hashimoto, I.; Matsumoto, T.; Thiemann, T.; Mataka, S. Synthesis of 1,2,9,10-tetrakis(N-phenylamino) [2.2]-metacyclophane by SMI2-mediated reductive coupling of diimine. Tetrahedron Lett. 2005, 46, 5277-9.
56. Nordlander, J. E.; Catalane, D. B.; Eberlein, T. H.; Farkas, L. V.; Howe, R. S.; Stevens, R. M.; Tripoulas, N. A.; Stansfield, R. E.; Cox, J. L.; Payne, M. J.; Viehbeck, A. Preparation of secondary-amines through efficient alkylation of N-substituted trifluoroacetamides. Tetrahedron Lett. 1978, 4987-90.
57. Lai, R. Y.; Surekha, K.; Hayashi, A.; Ozawa, F.; Liu, Y. H.; Peng, S. M.; Liu, S. T. Intra- and intermolecular hydroamination of alkynes catalyzed by ortho-metalated iridium complexes. Organometallics 2007, 26, 1062-8.
58. Ashton, P. R.; Chrystal, E. J. T.; Glink, P. T.; Menzer, S.; Schiavo, C.; Stoddart, J. F.; Tasker, P. A.; Williams, D. J. Doubly encircled and double-stranded pseudorotaxanes. Angew. Chem., Int. Ed. Engl. 1995, 34, 1869-71.